Enhancing Slow Wave Sleep in Depression

This pilot trial, registered at Wake Forest University Health Sciences and not yet recruiting as of mid-2026, asks a deceptively simple question: can we electrically nudge a depressed brain into spending more time in deep, restorative sleep — and would that actually help? The intervention is a wearable device worn during sleep that first reads the brain's electrical activity and then delivers precisely timed transcranial electrical stimulation to amplify the slow brain waves that define deep (slow-wave) sleep. Depression is well known to fragment and reduce slow-wave sleep, and that disruption is thought to worsen both mood and cognitive sharpness. Participants also wear an actigraphy watch around the clock and complete cognitive tests along with mood and sleep questionnaires throughout the study. The trial is designed as a randomized controlled pilot, meaning its primary job is to test feasibility and collect early signal, not to deliver a definitive answer. If it works, it would suggest a non-drug, non-invasive route to treating depression by repairing one of its core biological features rather than simply dampening symptoms. The results will inform whether a larger, fully powered trial is worth pursuing.

• No results are available yet — the trial has not begun recruiting as of the registered start date of 2026-05-26; all findings listed here reflect the study's pre-specified aims rather than outcomes.
• Primary aim: determine whether closed-loop transcranial electrical stimulation delivered during sleep can measurably increase slow-wave sleep (deep sleep) duration or intensity in adults with depression.
• Secondary aims: assess whether any slow-wave sleep gains produced by the device translate into improvements on cognitive performance tasks and self-reported mood ratings.

This is a pilot interventional randomized controlled trial enrolling adults with a diagnosis of depression. Participants will wear a non-invasive EEG-coupled device during sleep that detects slow-wave activity in real time and delivers responsive transcranial electrical stimulation to enhance it; an actigraphy watch provides continuous activity monitoring between sessions. Cognitive assessments and validated mood and sleep questionnaires are administered at multiple time points across the study. Sample size, number of nights of stimulation, and precise follow-up duration are not specified in the registered abstract; these details are classified as best-effort given the pre-recruitment status of the trial.

As a pilot, the study is almost certainly underpowered to detect modest clinical effects on mood or cognition, and any observed signals will require replication in a larger sample before conclusions can be drawn. The trial cannot yet tell us the optimal stimulation parameters (intensity, timing, frequency), the minimum number of treated nights needed for benefit, or whether effects persist after the device is removed. The absence of a sham-stimulation control description in the abstract leaves placebo response as an unresolved confound. The definitive next experiment would be a fully powered, sham-controlled RCT with longer follow-up and objective polysomnography alongside the wearable EEG.

This trial sits at the intersection of two active threads in the corpus: targeted neuromodulation of sleep architecture and the downstream cognitive and mood consequences of sleep disruption. It parallels [§33], which also uses a non-pharmacological intervention to manipulate sleep architecture in order to improve cognitive outcomes, though in an Alzheimer's/MCI population rather than depression, making the comparison useful for understanding how sleep-targeted interventions translate across neuropsychiatric diagnoses. It extends [§133], which documents the broader relationship between sleep deficiency and central nervous system health outcomes, by moving from observational characterisation to active intervention. The study also parallels [§32], which explores bidirectional links between disrupted sleep and mental-state changes in epilepsy, reinforcing the emerging view that sleep architecture is a mechanistic lever — not merely a symptom — across psychiatric and neurological conditions. Finally, the closed-loop brain-stimulation design echoes the logic of [§111], which targets another deep brain structure (the suprachiasmatic nucleus) via electrical stimulation to reshape sleep-related physiology, offering a useful methodological comparison point even though the target populations and exact mechanisms differ.

• TREAD: Time Restricted Eating Intervention for Alzheimer's Disease
  Direct methodological parallel: both are RCTs using a non-pharmacological, device-based intervention to improve sleep architecture and cognitive outcomes, differing mainly in target population (AD/MCI vs. depression).
• Sleep, Light, Circadian, Central Oxidative Stress
  Provides the observational mechanistic backdrop — sleep deficiency and circadian disruption driving cognitive and brain-health decline — that this trial is designed to experimentally reverse.
• Links Between Epileptic Activity, Sleep Disruption and Mental Content During Sleep
  Examines how disrupted sleep architecture causally affects mental state and cognition in epilepsy, offering a cross-diagnostic comparison of the same core hypothesis being tested here.
• Research on the Efficacy and Safety of Targeted Suprachiasmatic Nucleus Electrical Stimulation for Improving Metabolic Disorders in Patients With Stable Bipolar Disorder Comorbid With Obesity
  Uses electrical stimulation of a sleep-regulatory brain structure as a therapeutic strategy, making it a near-parallel in neuromodulation logic despite targeting metabolic rather than mood outcomes.
• Sleep and Performance
  Addresses the relationship between sleep quality and performance outcomes broadly, providing a useful empirical reference frame for interpreting any cognitive endpoints this trial reports.